It was more than fi ve decades ago when cellular reprogramming was fi rst shown by somatic cell nuclear transfer. Th ese seminal experiments show that somatic cells can revert to pluripotency by somatic cell nuclear transfer, proving the totipotency of their genome. Th rough later studies we learned that somatic cell fate is mainly driven by a specifi c set of transcription factors and solidifi ed by epigenetic mechanisms, which can be reverted by reprogramming activities in oocytes or embryonic stem cells. Th e knowledge gained in the past half a century culminated in the breakthrough discovery of induced pluripotency by Yamanaka and Takahashi in 2006 [1]. Th ey demonstrated that terminally diff erentiated cells can return to an embryonic-like pluripotent state (termed induced pluripotent stem cells (iPSCs)) by forced expression of four transcription factors (Oct4, Sox2, Klf4 and c-Myc) [1] . iPSC technology has since spurred a plethora of studies aimed at understanding the mechanism of reprogramming, modeling human diseases and developing cell-based therapies for degenerative conditions.
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Despite great enthusiasm and eff ort, iPSC-related research is hampered by the fact that iPSC generation is a slow and ineffi cient process, and that most iPSC derivation protocols entail modifi cations of the host genome. Th e most widely adopted method for generating iPSCs relies on integrating retroviral vectors. Th e process takes approximately 4 weeks and only 0.01 to 0.1% of the cells become iPSCs. In addition, there are serious concerns regarding the safety of these virally derived iPSCs. Th e integrated proviruses may cause insertional mutagenesis, bias the diff erentiation potential of iPSCs if not silenced, and lead to tumor formation once reactivated during the diff erentiation process [2] . People have tried to avoid these issues by generating transgene-free iPSCs using diff erent strategies, including non-integrative vectors, excisable vectors, and cell-penetrating proteins. Th e DNA-based methods that are ostensibly nonintegrating still require careful characterization of the iPSC genome to rule out random integration of small fragments of the vector. Th e removal of excisable vectors entails complex manipulations and prolonged culture, and still leaves a 'scar' in the genome in many cases. Moreover, none of the above mentioned technologies resolve the issue of slow kinetics and low effi ciency of iPSC generation [3] .
Can the 'three wishes' -safety, speed and effi ciency -of reprogramming ever be fulfi lled? A recent paper by Warren and colleagues [4] may have just provided an answer. Th e innovation of the study is centered on the use of synthetic mRNA, a previously underexplored route for delivery of reprogramming factors, in iPSC gener ation. In contrast to DNA-based vectors, the use of mRNA completely eliminates the risk of modifying the host genome. It has several advantages over the protein transduction approach: it is simpler and more effi cient, as one mRNA molecule is likely to undergo multiple rounds of translation before its degradation; and the proteins produced inside the cell have proper post-translational modifi cations, resulting in more precise localization and higher activity. Indeed, mRNA-based gene delivery has been shown to be highly effi cient in human stem and
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Recent development of a synthetic mRNA-based technology for effi cient reprogramming to pluripotency and cell fate conversion without any modifi cation to the genome has generated great interest among researchers and clinicians alike. It is hoped that this technology could contribute to unmet needs on several fronts of regenerative medicine, including mechanistic study of reprogramming, generation of safe induced pluripotent stem cells suitable for clinical applications, and derivation of desired cell types for cell-replacement therapy. We will discuss the technological advancements made by this synthetic mRNA methodology, its implications, as well as the challenges that lie ahead in the fi eld of regenerative medicine.
progenitor cells [5] . Furthermore, its safety has been demonstrated in clinical trials [6] . However, there are two major roadblocks to adapting this methodology to cellular reprogramming. First, mRNAs are rapidly turned over in the cell, which is incompatible with the requirement for sustained expression of reprogramming factors for about 2 weeks. Th is point is clearly illustrated in a recent study by Plews and colleagues [7] in which a single electroporation of mRNAs encoding OCT4, SOX2, KLF4, c-Myc and SV40 large T antigen resulted in only partially reprogrammed cells. After careful examination of the kinetics of reprogramming factor levels after mRNA transfection, Warren and colleagues [4] concluded that daily transfection is necessary to maintain the reprogram ming activities. Consequently, this strategy leads to the second caveat, which is the high cytotoxicity triggered by repeated transfection of foreign mRNA via an NF-κB-dependent anti-viral pathway. Th rough careful experi men tation, the authors overcame these issues by intro ducing a series of changes to the standard protocol to reduce the immunogenecity of synthetic RNA (removal of 5' triphosphates, incorporation of modifi ed ribo nucleo sides) and to suppress interferon signaling pathways (media supplementation of interferon inhibitor B18R). Armed with these innovations, they successfully developed an mRNA-based reprogramming protocol that is two times faster and 35-fold more effi cient than the viral one. Moreover, the global gene expression profi le of RNA-induced pluripotent stem cells (RiPSCs) more closely resembles human embryonic stem cells than virally derived iPSCs. As the authors pointed out, such a diff erence may be attributed to the absence of transgenes in RiPSCs. However, it is worth pointing out that other factors, such as the culture conditions that the cells are exposed to during reprogramming as well as the passage number of iPSCs, are known to aff ect the epigenetic state of iPSCs.
As shown in this study and others, the mRNA-based methodology also applies to directed diff erentiation of iPSCs and direct fate conversion between terminally diff erentiated cells. Other than improving effi ciency and safety of existing protocols, the mRNA-based technology can aid in the development of better protocols that ensure stable and complete conversion to the desired cell types, which are independent of exogenous factors. In other situations, synthetic mRNAs may be used to alter cell fate temporarily. For example, gene targeting by homologous recombination is extremely ineffi cient in human iPSCs, but it can be greatly improved in the naïve pluripotent state. However, such a state in human iPSCs requires overexpression of Oct4, Klf4 and Klf2 [8] . It is conceivable that these factors can be delivered as mRNA to induce the naïve pluripotent state without any modifi cations to the genome.
Th e synthetic mRNA technology developed by Warren and colleagues represents one of the few examples of major technical advancements in regenerative medicine. It is likely to accelerate the study of the mechanism of cellular reprogramming and the translation of research fi ndings into clinical practice. While being optimistic, we should also remain vigilant in studying the safety of the cells derived by this technology. For example, further studies are necessary to make sure that repeated transfections and prolonged inhibition of interferon signaling do not cause any lasting change in the cells or constitute a selection pressure for cells that are defi cient in innate immune response. More importantly, we and others recently showed that iPSCs derived by existing protocols (including RiPSCs) are equally prone to the accumulation and positive selection of mutations in tumor suppressor genes, oncogenes and genes important for cell cycle regulation [9, 10] . It is then logical to assume that not only does a great deal of research eff ort have to be focused on the development of effi cient nonintegrative approaches but also on novel methods limiting the accumulation of harmful mutations during the reprogramming process.
